US5196203A - Theophylline dosage form - Google Patents

Theophylline dosage form Download PDF

Info

Publication number
US5196203A
US5196203A US07/767,342 US76734291A US5196203A US 5196203 A US5196203 A US 5196203A US 76734291 A US76734291 A US 76734291A US 5196203 A US5196203 A US 5196203A
Authority
US
United States
Prior art keywords
release
active ingredient
stomach
pellet composition
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/767,342
Inventor
Garth Boehm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma International Pty Ltd
Original Assignee
FH Faulding and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FH Faulding and Co Ltd filed Critical FH Faulding and Co Ltd
Priority to US07/767,342 priority Critical patent/US5196203A/en
Application granted granted Critical
Publication of US5196203A publication Critical patent/US5196203A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

  • the present invention relates to a pharmaceutical composition in particular a pharmaceutical composition including a theophylline compound and to a method for preparing same.
  • 1,3-dimethylxanthine is a naturally occurring xanthine derivative and has been used as a bronchodilator, cardiotonic, diuretic and respiratory stimulant for over sixty years. Bronchodilatation is the major therapeutic property of theophylline and is achieved by inducing relaxation in the smooth muscle of the bronchi. Therefore theophylline is commonly used to relieve bronchospasm associated with asthma and chronic obstructive airways disease (COAD).
  • COAD chronic obstructive airways disease
  • Such prior art preparations still suffer from a number of disadvantages.
  • Such disadvantages include the fact that the preparations may exhibit dose dumping or fluctuations in plasma theophylline concentrations which may increase the likelihood of toxicity.
  • some degree of diurnal variation in plasma theophylline concentrations have been noted.
  • bioavailability of prior art preparations may be compromised by food. This is important since complex dosage regimens may lead to non-compliance.
  • a pharmaceutical sustained release pellet composition including
  • a core element including at least one active ingredient including a theophylline compound
  • a core coating for the core element which is partially soluble at a highly acidic pH to provide a slow rate of release of theophylline compound and wherein the theophylline compound is available for absorption at a relatively constant faster rate in the intestine over an extended period of time.
  • the core coating in use, generates a dissolution profile for the pellet composition which is equal to or greater than the minimum dissolution required to provide substantial bioequivalence with a capsule or tablet containing the at least one active ingredient in a sustained release form.
  • sustained release pellet composition we mean release of theophylline at such a rate that blood levels are maintained within the therapeutic range but below toxic levels over an extended period of time e.g. 12 to 24 hours or greater.
  • the rate of release at the less acidic to basic pH is greater than the rate of release at the highly acidic pH, preferably 1.2 to three times greater.
  • the rate of release of theophylline compound may be substantially zero at a highly acidic pH. Where some release of theophylline compound does occur in the stomach, this may occur at a relatively constant rate.
  • the pharmaceutical pellet composition according to the present invention may include a plurality of coated core elements.
  • the pharmaceutical pellet composition may be provided in any suitable unit dosage form.
  • An encapsulated form may be used.
  • the encapsulated pharmaceutical pellet composition may thus provide, in use, a blood profile in a patient to be treated which is substantially bio-equivalent to commercial capsules or tablets, including theophylline in a sustained release form, but reduces, or eliminates one or more of the difficulties of prior art formulations discussed above.
  • the pharmaceutical pellet composition may be provided in a tablet form.
  • a tablet may be formed by compression of the pellets, optionally with the addition of suitable excipients.
  • a first dissolution profile may be measured at a pH level approximating that of the stomach.
  • At least a second dissolution profile may be measured at pH levels approximating that of at least one point in the intestine.
  • a highly acidic pH may simulate the stomach and a less acidic to basic pH may simulate the intestine.
  • highly acidic pH as used herein we mean a pH in the range of approximately 1 to 4
  • less acidic to basic pH we mean a pH of greater than 4 up to approximately 7.5, preferably approximately 6 to 7.5.
  • a pH of approximately 1.2 may be used to simulate the pH of the stomach.
  • a pH of approximately 6.0 to 7.5 preferably 7.5 may be used to simulate the pH of the intestine.
  • Bio-equivalence means that the area under the curve (AUC) and Cmax from a plot of blood concentration of active ingredient versus time are within certain designated requirements by Health authorities. For example the blood levels achieved may be plus or minus 20% in 80% or more of the subjects when compared to an equivalent product.
  • Dissolution profile as used herein, means a plot of amount of active ingredient released as a function of time.
  • the dissolution profile may be measured utilising the Drug Release Test (724) which incorporates standard test USPXXII 1990. (Test(711)).
  • a profile is characterised by the test conditions selected.
  • the dissolution profile may be generated at a preselected shaft speed, temperature and pH of the dissolution media.
  • theophylline compound is provided in a sustained release pellet form significantly less fluctuations in plasma theophylline concentrations at steady state over a 24 hour period are generated. This is expected to result in less toxic and more effective therapeutic activity.
  • the pharmaceutical pellet composition according to the present invention generates less diurnal variation and less peak to trough variations in plasma theophylline concentrations than prior art preparations.
  • the pharmaceutical pellet composition according to the present invention shows no evidence of dose dumping.
  • the bioavailability of the theophylline generated from the pharmaceutical pellet composition is not compromised by food so that compliance will improve as the product may be taken without regard to meals.
  • the theophylline compound in the pharmaceutical pellet composition may take any suitable form.
  • the theophylline compound may be provided in an anhydrous or hydrous form.
  • the theophylline compound may be provided in a salt form.
  • theophylline compound as used herein we mean a compound selected from theophylline and derivatives thereof and other xanthines and derivatives thereof.
  • An ethylene diamine salt of theophylline may be used.
  • FIG. 1 shows the dissolution profile for the Pellet Composition B, defined hereafter.
  • FIG. 2 represents a dissolution profile for the Pellet Composition A, defined hereafter.
  • FIG. 3 is a graphic representation of a single dose bioavailability study for elixir pellet capsules according to the invention administered after feeding and after fasting as reported in Table 5.
  • FIG. 4 is a graphic representation of the multiple dose bioavailability study comparing theophylline pellet capsules according to the invention, Neulin®, and Theo-Dur® reported in Phase II of Example 2.
  • the active ingredient may be available for absorption even in regions of the gastrointestinal tract which are not sufficiently alkaline to dissolve the enteric core coating component.
  • the active ingredient is available for absorption in an absorption region substantially immediately after the pyloric sphincter in the patient.
  • an absorption region may generally be characterised by a pH between approximately 1.2 and 5.5.
  • Absorption will substantially occur in the small intestine but since absorption will continue over an extended period of time, then some absorption will occur additionally some way into the large intestine.
  • sustained release pharmaceutical pellet composition including a core element including at least one active ingredient including a theophylline compound;
  • a hybrid core coating which coating provides a relatively constant low rate of release at a highly acidic pH and a relatively constant higher rate of release at a less acidic to basic pH over an extended period of time.
  • the hybrid core coating may include
  • At least one enteric polymer which is substantially insoluble at acidic pH but at least partially soluble at a less acidic to basic pH
  • At least one component which is at least partially soluble at acidic pH is at least one component which is at least partially soluble at acidic pH.
  • the enteric polymer is readily soluble at a less acidic to basic pH.
  • the at least partially water soluble component is a readily water-soluble component.
  • the rate of dissolution at highly acidic pH of the hybrid core coating will depend on the amount of the at least partially water soluble component, and the thickness of the coating.
  • Typical core coatings may be in the range of approximately 5 to 200 um, preferably approximately 40 to 80 um. It will be understood, accordingly, that the rate of absorption may be modified by modifying the thickness and/or the composition of the hybrid core coating.
  • the dissolution rate may be controlled by modifying the concentration of the partially acid soluble and enteric component as well as the thickness of the polymer film.
  • the dissolution rate may be controlled by modifying the concentration of the enteric polymer component in the hybrid core coating.
  • the hybrid core coating may include
  • the hybrid core coating excluding filler and plasticiser, of at least one insoluble matrix polymer selected from the group consisting of acrylic ester polymers, methacrylic ester polymers and mixtures thereof;
  • the hybrid core coating excluding filler and plasticiser, of at least one enteric polymer selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methyl-cellulose phthalate (HPMCP), polyvinyl acetate phthalate, methacrylic acid copolymer, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate and mixtures thereof; and
  • enteric polymer selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methyl-cellulose phthalate (HPMCP), polyvinyl acetate phthalate, methacrylic acid copolymer, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate and mixtures thereof; and
  • the hybrid core coating excluding filler and plasticiser of an at least partially acid soluble component selected from polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol having a molecular weight of from 1700 to 20,000, polyvinyl alcohol and monomers therefor and mixtures thereof.
  • an at least partially acid soluble component selected from polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol having a molecular weight of from 1700 to 20,000, polyvinyl alcohol and monomers therefor and mixtures thereof.
  • enteric polymers include synthetic resin bearing carboxyl groups.
  • the methacrylic acid copolymer sold under the trade designation "Eudragit L30D" has been found to be suitable.
  • the at least one enteric polymer may be present in the coating in an amount of from approximately 1 to 30% by weight, preferably 2.5 to 10% by weight, based on the total weight of the hybrid core coating excluding weight of filler and plasticiser.
  • the at least partially acid-soluble component may preferably be selected from polymers such as polyethylene glycol, polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose or monomers such as sugars, salts, or organic acids and mixtures thereof.
  • the at least partially acid-soluble component may be present in the coating in amounts of from approximately 1 to 60%, preferably 20 to 40% by weight, based on the total weight of the hybrid core coating excluding weight of filler and plasticisers.
  • the at least one insoluble matrix polymer may preferably be selected from polymers or copolymers of acrylates or methacrylates having a low quaternary ammonium content may be used.
  • the acrylic acid ethyl ester: methacrylic acid methyl ester (70:30) copolymer sold under the trade designation "Eudragit NE30D" has been found to be suitable.
  • the at least one insoluble matrix polymer may be present in the coating in an amount of from approximately 10 to 95% by weight preferably 40 to 70% by weight based on the total weight of the hybrid core coating excluding weight of filler and plasticiser.
  • the weight ratio of enteric polymer:insoluble matrix polymer:water soluble excipient is approximately 2.5:70:20 to 10:40:40.
  • the hybrid core coating may further include
  • At least one plasticiser at least one plasticiser; and optionally
  • At least one filler is at least one filler.
  • the hybrid core coating may preferably include
  • the hybrid core coating of at least one plasticiser selected from diethyl phthalate, triethyl citrate, triethyl acetyl citrate, triacetin, tributyl citrate, polyethylene glycol having a molecular weight of from 200 to less than 1700 and glycerol and the like; and
  • a filler selected from insoluble materials such as silicon dioxide, titanium dioxide, talc, alumina, starch, kaolin, polacrilin potassium, powdered cellulose, and microcrystalline cellulose and mixtures thereof.
  • plasticiser used may be largely dictated by the polymer used in the coating formulation, and the solubility of the plasticiser in the coating media.
  • the plasticiser may function to improve the physical stability of the pellet.
  • a plasticiser is particularly preferred where the enteric polymer is of relatively low molecular weight.
  • acid or water soluble plasticisers can also be used to function as the partially acid soluble component.
  • the plasticiser may be present in any suitable effective amount. Amounts of from approximately 25 to 50% by weight preferably 5 to 30% by weight based on the total weight of the hybrid core coating, excluding filler, have been found to be suitable.
  • Preferred hybrid core coating include
  • the hybrid core coating may further include at least one filler.
  • the at least one filler may be selected from those insoluble fillers listed below for the manufacture of the core element.
  • the filler may be present in any suitable effective amount. Amounts of from 0 to approximately 75% by weight, preferably 0-50% by weight based on the total weight of the core coating have been found to be suitable.
  • the core element of the pharmaceutical composition may include
  • At least one binding agent at least one binding agent.
  • the theophylline compound may be present in any suitable effective amount.
  • the theophylline compound may be present in amounts of approximately 10 to 95% by weight, preferably approximately 20 to 90% by weight, based on the total weight of the core element.
  • the binding agent may be present in amounts of from approximately 0 to 45% by weight preferably approximately 0 to 10% by weight based on the total weight of the core element.
  • the binding agent may be of any suitable type. Suitable binders may be selected from polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose and hydroxyethyl cellulose, sugars and mixtures thereof.
  • the binding agent may be provided in the form of a granulating solution. An aqueous or organic solvent may be included. Methanol, ethanol or mixtures thereof may be used as solvents.
  • the size and amount of the core seed may vary substantially from approximately 425 um to 1700 um depending upon the amount of active ingredient to be included. Accordingly, the core seeds may vary from approximately 5 to 95% by weight, preferably 10 to 75% by weight based on the total weight of the core element. The core seed may be of such a diameter to provide a final core element having a diameter of approximately 500 to 2000 um.
  • the core seed may be of any suitable type.
  • a sugar or an active core seed may be used.
  • the core element may further include other carriers or excipients, fillers, stabilizing agents and colorants.
  • Suitable fillers may be selected from insoluble materials such as silicon dioxide, titanium dioxide, talc, alumina, starch, kaolin, polacrilin potassium, powdered cellulose, and microcrystalline cellulose and mixtures thereof.
  • Soluble fillers may be selected from mannitol, sucrose, lactose, dextrose, sodium chloride, sorbitol and mixtures thereof.
  • the filler may be present in amounts up to approximately 75% by weight based on the total weight of the core element.
  • Typical core formulations may be prepared in the amounts as follows:
  • the hybrid core coating composition may be provided in the form of a solution, dispersion or suspension.
  • the solvent may be present in amounts of from approximately 25 to 97% by weight based on the total weight of the hybrid core coating composition.
  • the solvent for the polymer may be a solvent such as water, methanol, ethanol, methylene chloride and mixtures thereof.
  • the diluting medium may be present in amounts of from approximately 25 to 97% by weight based on the total weight of the hybrid core coating composition and is comprised predominantly of water.
  • Typical hybrid core coating formulations may be prepared in the amounts as follows:
  • Sufficient plasticiser may be added to ensure film formation.
  • a pharmaceutical sustained release product in a unit dosage form including a plurality of pellets, each pellet including
  • a core element including a theophylline compound
  • a core coating for the core element which is partially soluble at a highly acidic pH and wherein the active ingredient is available for absorption at a relatively constant rate in the small intestine over an extended period of time.
  • Spray coating of core elements may be undertaken utilising bottom or top located spray nozzles.
  • a bottom spray nozzle may reside proximate to the base of the fluidised bed facing upwards while a top spraying nozzle is located above the contents of the bed and facing downwards.
  • the method may include the preliminary steps of providing
  • the at least one binding agent is provided in a granulating solution.
  • the coating step may be conducted as a spheronisation process.
  • the spheronisation process includes contacting the core seeds with the active ingredient and simultaneously adding the granulating solution thereto.
  • the spheronisation process may be conducted in a spheronising machine.
  • the method according to the present invention may further include providing the active ingredient and binder in a solution or slurry of a solvent and spraying the core seeds with the solution or slurry.
  • the spraying step may be conducted in a fluidised bed chamber.
  • the method for preparing a core element may include providing
  • the solvent may be an aqueous or organic solvent or mixtures thereof.
  • the solvent may be present in an amount effective to allow the ingredients to be extruded.
  • the core elements formed are then subjected to a drying step.
  • the drying step may be conducted in a fluidised bed or drying oven.
  • the sustained release pharmaceutical pellet composition may be administered under a similar dosage regimen to that used in the prior art.
  • the multi-pellet encapsulated form may for example be administered every twelve or twenty-four hours in sustained release forms.
  • the pharmaceutical pellet composition may be in multi-pellet encapsulated, sprinkle sachet or tableted forms.
  • a method of treating cardiotonic, diuretic or respiratory conditions in patients requiring such treatment which method includes administering to a patient an effective amount of a pharmaceutical sustained release pellet composition as described above.
  • the method of treating the abovementioned conditions according to this aspect of the present invention provides an advantage in reducing side effects associated with prior art sustained release products in a tablet or capsule form as described above.
  • side effects include headache, palpitation, dizzyness, nausea, hypotension, visual disturbance, insomnia, restlessness, confusion and diuresis.
  • the sugar seeds were placed in a spheroniser.
  • the sugar seeds were then coated with a dry mixture of the active ingredients and inactive excipients whilst concimittantly adding a solution of the binder components.
  • the wet cores so formed were then dried in a fluidised bed dryer for 1 hour.
  • the components of the extruded core composition were admixed to form an extrudable composition.
  • the composition was then extruded through a side plate extruder and the extrudate marumerised to form wet cores.
  • the wet cores so formed were then placed in a fluid bed dryer for 1 hour.
  • the dried spheronised cores 1 and 2 were then placed in a fluid bed coating apparatus.
  • the hybrid core coating compositions A and B were then sprayed onto the cores 1 and 2 to form pellets A and B respectively. At the conclusion of the process, the pellets were fluid bed dried.
  • a dissolution test was conducted on the pellet compositions A and B utilising the test method USPXXII 1990. (Test 711).
  • a sample is dissolved in an aqueous medium previously degassed and equilibrated to 37° C.
  • the media are USP pH 1.2 media without enzymes and pH 7.5 phosphate buffer.
  • a sample of known volume is withdrawn at designated time intervals from the bath as directed and subjected to a suitable assay procedure.
  • the mg of theophylline released as a function of time is plotted as the dissolution profile.
  • the baskets containing the samples were rotated at approximately 50 r.p.m. and the aqueous medium maintained at approximately 37° C.
  • Phase I was a three-way crossover single dose study to compare the relative bioavailability of Pellet Capsules according to the present invention with the reference product Elixophyllin® elixir, a rapid release formulation demonstrated to be completely bioavailable. The effect of food on the bioavailability of Pellet Capsules was also examined.
  • Both products were administered to eighteen healthy, non-smoking, adult subjects.
  • the subjects were randomized by weight into three equal size groups I, II and III. These groups were then randomly sorted into either regimens A, B or C.
  • a - Elixophyllin® elixir (150 mg in 28 mL), administered with 152 mL water on two separate occasions six hours apart, to give a total of 300 mg of theophylline.
  • the washout period between each dosage regimen was one week.
  • Pellet Capsules fulfill the requirements of a sustained release product. While a single 300 mg dose of Pellet Capsules achieves a peak plasma concentration of 4.5 mg/L irrespective of the presence of food, the same dose of the reference product Elixophyllin® would achieve a peak plasma concentration approximately twice that value. In addition the time taken to reach peak plasma concentration is longer for Pellet Capsules compared with Elixophyllin®. This demonstrates that Pellet Capsules can provide therapeutic plasma theophylline concentrations within the defined narrow therapeutic concentration range with a decreased probability of theophylline toxicity due to lower peak to trough variations in blood levels.
  • Phase II was a three-way crossover multiple dose study to compare the plasma steady state theophylline concentrations produced by three different formulations; Pellet Capsule pelletised sustained release capsules, Theo-Dur® sustained release tablets and Neulin® tablets.
  • Neulin® is an immediate release theophylline product.
  • the efficacy and toxicity of theophylline is directly related to the plasma theophylline concentration.
  • the optimum therapeutic concentration range is 5 to 20 mg/L (Hendeles and Weinberger, 1983).
  • theophylline has a narrow therapeutic index. Plasma concentrations below 5 mg/L generally result in less than optimal bronchodilatation while concentrations above 20 mg/L are often associated with theophylline toxicity.
  • Theophylline is used prophylactically in the management of asthma and chronic obstructive airways disease (COAD), requiring continuous theophylline therapy for prolonged periods of time.
  • COAD chronic obstructive airways disease
  • Pellet Capsules are administered at the appropriate dosing rate, the plasma theophylline concentrations observed are maintained within the defined therapeutic range.
  • the multiple dose study confirms the results of the single dose study and highlights the additional advantages of significantly less diurnal variation as percent fluctuations in plasma theophylline concentrations at steady state.

Abstract

A pH-dependent sustained release pharmaceutical pellet composition and a method of administering the same to a patient at a predetermined dosage and interval, said pellet composition comprising: a core element containing a therapeutically effective amount of theophylline, xanthine or a derivative thereof as the active ingredient and a coating on said core element which comprises the following components:
(a) at least 40% of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and contributes to the control of the rate of release of the active ingredient in the stomach and intestines;
(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;
(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach;
said percentages being by weight based on total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval, said coated core element having a diameter of from 510 to 2400 microns.

Description

This is a continuation of application Ser. No. 457,198, filed Dec. 29, 1989, now abandoned.
The present invention relates to a pharmaceutical composition in particular a pharmaceutical composition including a theophylline compound and to a method for preparing same.
As is known in the prior art, 1,3-dimethylxanthine, is a naturally occurring xanthine derivative and has been used as a bronchodilator, cardiotonic, diuretic and respiratory stimulant for over sixty years. Bronchodilatation is the major therapeutic property of theophylline and is achieved by inducing relaxation in the smooth muscle of the bronchi. Therefore theophylline is commonly used to relieve bronchospasm associated with asthma and chronic obstructive airways disease (COAD).
Over the past twenty years the pharmacodynamics and pharmacokinetics of theophylline have been extensively investigated and a therapeutic plasma concentration range has been defined. In an attempt to maintain a constant concentration of theophylline within this range during chronic therapy, a number of prior art sustained release preparations have been marketed.
However, such prior art preparations still suffer from a number of disadvantages. Such disadvantages include the fact that the preparations may exhibit dose dumping or fluctuations in plasma theophylline concentrations which may increase the likelihood of toxicity. Moreover, some degree of diurnal variation in plasma theophylline concentrations have been noted. Further, bioavailability of prior art preparations may be compromised by food. This is important since complex dosage regimens may lead to non-compliance.
Accordingly, it is an object of the present invention to overcome, or at least alleviate, one or more of the difficulties related to the prior art.
Accordingly, in a first aspect of the present invention there is provided a pharmaceutical sustained release pellet composition including
a core element including at least one active ingredient including a theophylline compound; and
a core coating for the core element which is partially soluble at a highly acidic pH to provide a slow rate of release of theophylline compound and wherein the theophylline compound is available for absorption at a relatively constant faster rate in the intestine over an extended period of time.
Preferably, the core coating, in use, generates a dissolution profile for the pellet composition which is equal to or greater than the minimum dissolution required to provide substantial bioequivalence with a capsule or tablet containing the at least one active ingredient in a sustained release form.
By "sustained release pellet composition" we mean release of theophylline at such a rate that blood levels are maintained within the therapeutic range but below toxic levels over an extended period of time e.g. 12 to 24 hours or greater.
Desirably, for some applications of the invention, the rate of release at the less acidic to basic pH is greater than the rate of release at the highly acidic pH, preferably 1.2 to three times greater. In some applications, the rate of release of theophylline compound may be substantially zero at a highly acidic pH. Where some release of theophylline compound does occur in the stomach, this may occur at a relatively constant rate.
The pharmaceutical pellet composition according to the present invention may include a plurality of coated core elements.
The pharmaceutical pellet composition may be provided in any suitable unit dosage form. An encapsulated form may be used. The encapsulated pharmaceutical pellet composition may thus provide, in use, a blood profile in a patient to be treated which is substantially bio-equivalent to commercial capsules or tablets, including theophylline in a sustained release form, but reduces, or eliminates one or more of the difficulties of prior art formulations discussed above.
The pharmaceutical pellet composition may be provided in a tablet form. A tablet may be formed by compression of the pellets, optionally with the addition of suitable excipients.
A first dissolution profile may be measured at a pH level approximating that of the stomach. At least a second dissolution profile may be measured at pH levels approximating that of at least one point in the intestine.
A highly acidic pH may simulate the stomach and a less acidic to basic pH may simulate the intestine. By the term "highly acidic pH" as used herein we mean a pH in the range of approximately 1 to 4, by the term "less acidic to basic pH" we mean a pH of greater than 4 up to approximately 7.5, preferably approximately 6 to 7.5.
A pH of approximately 1.2 may be used to simulate the pH of the stomach.
A pH of approximately 6.0 to 7.5 preferably 7.5 may be used to simulate the pH of the intestine.
"Bio-equivalence" as used herein, means that the area under the curve (AUC) and Cmax from a plot of blood concentration of active ingredient versus time are within certain designated requirements by Health Authorities. For example the blood levels achieved may be plus or minus 20% in 80% or more of the subjects when compared to an equivalent product.
"Dissolution profile" as used herein, means a plot of amount of active ingredient released as a function of time. The dissolution profile may be measured utilising the Drug Release Test (724) which incorporates standard test USPXXII 1990. (Test(711)). A profile is characterised by the test conditions selected. Thus the dissolution profile may be generated at a preselected shaft speed, temperature and pH of the dissolution media.
It will be understood that since the theophylline compound is provided in a sustained release pellet form significantly less fluctuations in plasma theophylline concentrations at steady state over a 24 hour period are generated. This is expected to result in less toxic and more effective therapeutic activity.
Similarly, it has been found that the pharmaceutical pellet composition according to the present invention generates less diurnal variation and less peak to trough variations in plasma theophylline concentrations than prior art preparations.
Moreover, the pharmaceutical pellet composition according to the present invention shows no evidence of dose dumping. The bioavailability of the theophylline generated from the pharmaceutical pellet composition is not compromised by food so that compliance will improve as the product may be taken without regard to meals.
The theophylline compound in the pharmaceutical pellet composition may take any suitable form. The theophylline compound may be provided in an anhydrous or hydrous form. The theophylline compound may be provided in a salt form. By the term "theophylline compound", as used herein we mean a compound selected from theophylline and derivatives thereof and other xanthines and derivatives thereof. An ethylene diamine salt of theophylline may be used.
FIG. 1 shows the dissolution profile for the Pellet Composition B, defined hereafter.
FIG. 2 represents a dissolution profile for the Pellet Composition A, defined hereafter.
FIG. 3 is a graphic representation of a single dose bioavailability study for elixir pellet capsules according to the invention administered after feeding and after fasting as reported in Table 5.
FIG. 4 is a graphic representation of the multiple dose bioavailability study comparing theophylline pellet capsules according to the invention, Neulin®, and Theo-Dur® reported in Phase II of Example 2.
The active ingredient may be available for absorption even in regions of the gastrointestinal tract which are not sufficiently alkaline to dissolve the enteric core coating component.
Thus the active ingredient is available for absorption in an absorption region substantially immediately after the pyloric sphincter in the patient. Such an absorption region may generally be characterised by a pH between approximately 1.2 and 5.5.
Absorption will substantially occur in the small intestine but since absorption will continue over an extended period of time, then some absorption will occur additionally some way into the large intestine.
Accordingly, in a preferred aspect according to the present invention there is provided
a sustained release pharmaceutical pellet composition including a core element including at least one active ingredient including a theophylline compound; and
a hybrid core coating which coating provides a relatively constant low rate of release at a highly acidic pH and a relatively constant higher rate of release at a less acidic to basic pH over an extended period of time.
The hybrid core coating may include
at least one insoluble matrix polymer;
at least one enteric polymer which is substantially insoluble at acidic pH but at least partially soluble at a less acidic to basic pH;
at least one component which is at least partially soluble at acidic pH.
It has been found necessary in order to achieve a slow rate of release at acidic pH of theophylline and a faster relatively constant rate of release over an extended period of time to include the above three components in the hybrid core coating.
Preferably the enteric polymer is readily soluble at a less acidic to basic pH.
Preferably the at least partially water soluble component is a readily water-soluble component.
Accordingly the hybrid core coating may include an effective amount of
a matrix polymer which is substantially insoluble independent of pH
an enteric polymer whose solubility is pH dependent, and
an at least partially water soluble component.
The rate of dissolution at highly acidic pH of the hybrid core coating will depend on the amount of the at least partially water soluble component, and the thickness of the coating. Typical core coatings may be in the range of approximately 5 to 200 um, preferably approximately 40 to 80 um. It will be understood, accordingly, that the rate of absorption may be modified by modifying the thickness and/or the composition of the hybrid core coating.
Once a minimum amount of the at least one partially soluble component and/or the maximum thickness of the coating to achieve the minimum dissolution profile at an highly acidic pH has been established, then it is simply a matter of design choice to adjust the composition and/or thickness of coating as desired.
It has been found that by manipulating the partially acid soluble component, and the at least one enteric component, one can modify the release properties of the polymer coating. With theophylline as the active substance, dissolution is slow at an acidic pH and increases substantially at a less acidic to basic pH. Moreover, the dissolution rate may be controlled by modifying the concentration of the partially acid soluble and enteric component as well as the thickness of the polymer film.
Moreover, the dissolution rate may be controlled by modifying the concentration of the enteric polymer component in the hybrid core coating.
Accordingly in a preferred aspect the hybrid core coating may include
approximately 10 to 95% based on the total weight of the hybrid core coating, excluding filler and plasticiser, of at least one insoluble matrix polymer selected from the group consisting of acrylic ester polymers, methacrylic ester polymers and mixtures thereof;
approximately 1 to 30% by weight based on the total weight of the hybrid core coating, excluding filler and plasticiser, of at least one enteric polymer selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methyl-cellulose phthalate (HPMCP), polyvinyl acetate phthalate, methacrylic acid copolymer, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate and mixtures thereof; and
approximately 1 to 60% by weight based on the total weight of the hybrid core coating excluding filler and plasticiser of an at least partially acid soluble component selected from polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol having a molecular weight of from 1700 to 20,000, polyvinyl alcohol and monomers therefor and mixtures thereof.
Particularly preferred enteric polymers include synthetic resin bearing carboxyl groups. The methacrylic acid copolymer sold under the trade designation "Eudragit L30D" has been found to be suitable.
The at least one enteric polymer may be present in the coating in an amount of from approximately 1 to 30% by weight, preferably 2.5 to 10% by weight, based on the total weight of the hybrid core coating excluding weight of filler and plasticiser.
The at least partially acid-soluble component may preferably be selected from polymers such as polyethylene glycol, polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose or monomers such as sugars, salts, or organic acids and mixtures thereof.
The at least partially acid-soluble component may be present in the coating in amounts of from approximately 1 to 60%, preferably 20 to 40% by weight, based on the total weight of the hybrid core coating excluding weight of filler and plasticisers.
The at least one insoluble matrix polymer may preferably be selected from polymers or copolymers of acrylates or methacrylates having a low quaternary ammonium content may be used. The acrylic acid ethyl ester: methacrylic acid methyl ester (70:30) copolymer sold under the trade designation "Eudragit NE30D" has been found to be suitable.
The at least one insoluble matrix polymer may be present in the coating in an amount of from approximately 10 to 95% by weight preferably 40 to 70% by weight based on the total weight of the hybrid core coating excluding weight of filler and plasticiser.
Preferably the weight ratio of enteric polymer:insoluble matrix polymer:water soluble excipient is approximately 2.5:70:20 to 10:40:40.
The hybrid core coating may further include
at least one plasticiser; and optionally
at least one filler.
The hybrid core coating may preferably include
approximately 2.5 to 50% by weight based on the total weight of the hybrid core coating of at least one plasticiser selected from diethyl phthalate, triethyl citrate, triethyl acetyl citrate, triacetin, tributyl citrate, polyethylene glycol having a molecular weight of from 200 to less than 1700 and glycerol and the like; and
0 to approximately 75% by weight based on the total weight of the hybrid core coating of a filler selected from insoluble materials such as silicon dioxide, titanium dioxide, talc, alumina, starch, kaolin, polacrilin potassium, powdered cellulose, and microcrystalline cellulose and mixtures thereof.
It will be understood that the plasticiser used may be largely dictated by the polymer used in the coating formulation, and the solubility of the plasticiser in the coating media. The plasticiser may function to improve the physical stability of the pellet. A plasticiser is particularly preferred where the enteric polymer is of relatively low molecular weight. It should be noted that acid or water soluble plasticisers can also be used to function as the partially acid soluble component.
The plasticiser may be present in any suitable effective amount. Amounts of from approximately 25 to 50% by weight preferably 5 to 30% by weight based on the total weight of the hybrid core coating, excluding filler, have been found to be suitable.
Preferred hybrid core coating include
______________________________________                                    
(Insol. matrix)  Ethyl cellulose   40-70%                                 
(Enteric polymer)                                                         
                 Hydroxypropylmethyl                                      
                                   2.5-10%                                
                 cellulose phthalate                                      
(Acid-soluble)   Polyethylene glycol                                      
                                   20-40%                                 
(Plasticiser)    Diethyl phthalate 2.5-30%                                
           or                                                             
(Insol. matrix)  Eudragit NE30D    40-70%                                 
(Enteric polymer)                                                         
                 Eudragit L30D     2.5-10%                                
(Acid-soluble)   polyethylene glycol 6000 NF                              
                                   20-40%                                 
(Plasticiser)    Triethylcitrate   2.5-30%                                
______________________________________
As stated above the hybrid core coating may further include at least one filler. The at least one filler may be selected from those insoluble fillers listed below for the manufacture of the core element.
The filler may be present in any suitable effective amount. Amounts of from 0 to approximately 75% by weight, preferably 0-50% by weight based on the total weight of the core coating have been found to be suitable.
In a preferred aspect of the present invention the core element of the pharmaceutical composition may include
an effective amount of a theophylline compound;
at least one core seed; and
at least one binding agent.
The theophylline compound may be present in any suitable effective amount. The theophylline compound may be present in amounts of approximately 10 to 95% by weight, preferably approximately 20 to 90% by weight, based on the total weight of the core element. The binding agent may be present in amounts of from approximately 0 to 45% by weight preferably approximately 0 to 10% by weight based on the total weight of the core element.
The binding agent may be of any suitable type. Suitable binders may be selected from polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose and hydroxyethyl cellulose, sugars and mixtures thereof. The binding agent may be provided in the form of a granulating solution. An aqueous or organic solvent may be included. Methanol, ethanol or mixtures thereof may be used as solvents.
The size and amount of the core seed may vary substantially from approximately 425 um to 1700 um depending upon the amount of active ingredient to be included. Accordingly, the core seeds may vary from approximately 5 to 95% by weight, preferably 10 to 75% by weight based on the total weight of the core element. The core seed may be of such a diameter to provide a final core element having a diameter of approximately 500 to 2000 um.
The core seed may be of any suitable type. A sugar or an active core seed may be used.
The core element may further include other carriers or excipients, fillers, stabilizing agents and colorants. Suitable fillers may be selected from insoluble materials such as silicon dioxide, titanium dioxide, talc, alumina, starch, kaolin, polacrilin potassium, powdered cellulose, and microcrystalline cellulose and mixtures thereof. Soluble fillers may be selected from mannitol, sucrose, lactose, dextrose, sodium chloride, sorbitol and mixtures thereof.
The filler may be present in amounts up to approximately 75% by weight based on the total weight of the core element.
Typical core formulations may be prepared in the amounts as follows:
______________________________________                                    
Spheronisation                                                            
            Theophylline     20-90%                                       
            Core seeds       10-75%                                       
            hydroxypropyl cellulose                                       
                             0.1-10%                                      
Extrusion                                                                 
            Theophylline     20-90%                                       
(extrusion agent)                                                         
            microcrystalline cellulose                                    
                              1-20%                                       
            hydroxypropyl cellulose                                       
                             0.1-10%                                      
(filler)    lactose           0-60%                                       
______________________________________
The hybrid core coating composition may be provided in the form of a solution, dispersion or suspension.
The solvent may be present in amounts of from approximately 25 to 97% by weight based on the total weight of the hybrid core coating composition. The solvent for the polymer may be a solvent such as water, methanol, ethanol, methylene chloride and mixtures thereof.
The diluting medium may be present in amounts of from approximately 25 to 97% by weight based on the total weight of the hybrid core coating composition and is comprised predominantly of water.
Typical hybrid core coating formulations may be prepared in the amounts as follows:
______________________________________                                    
    Core Coating Formulation                                              
A.  Insoluble matrix polymer                                              
                     40-70                                                
    Enteric          2.5-10       %                                       
    Acid soluble     20-40        excluding solvent                       
    Plasticiser      2.5-30                                               
    Solvent          85-97%       of total coating                        
                                  formula.                                
B.  For aqueous redispersion or suspension of polymers                    
    formulation A becomes:                                                
Insoluble matrix polymer                                                  
                 40-70                                                    
Enteric          2.5-10         %                                         
Acid soluble     20-40          excluding solvent                         
Plasticiser      2.5-30                                                   
Water            75-97%         of total coating                          
                                formula                                   
______________________________________
Sufficient plasticiser may be added to ensure film formation.
In a further aspect of the present invention, there is provided a pharmaceutical sustained release product in a unit dosage form including a plurality of pellets, each pellet including
a core element including a theophylline compound; and
a core coating for the core element which is partially soluble at a highly acidic pH and wherein the active ingredient is available for absorption at a relatively constant rate in the small intestine over an extended period of time.
Spray coating of core elements may be undertaken utilising bottom or top located spray nozzles. A bottom spray nozzle may reside proximate to the base of the fluidised bed facing upwards while a top spraying nozzle is located above the contents of the bed and facing downwards.
The method may include the preliminary steps of providing
a theophylline compound;
at least one binding agent;
at least one core seed; and
coating the core seeds with the theophylline compound and binding agent to form a core element.
In a preferred form the at least one binding agent is provided in a granulating solution. In this form the coating step may be conducted as a spheronisation process. The spheronisation process includes contacting the core seeds with the active ingredient and simultaneously adding the granulating solution thereto. The spheronisation process may be conducted in a spheronising machine.
In an alternative aspect of the present invention, the method according to the present invention may further include providing the active ingredient and binder in a solution or slurry of a solvent and spraying the core seeds with the solution or slurry. The spraying step may be conducted in a fluidised bed chamber.
In a further alternative aspect of the present invention, the method for preparing a core element may include providing
a theophylline compound;
at least one binding agent; and
an effective amount of a solvent,
mixing the ingredients; and
subjecting the ingredients to an extrusion followed by marumerisation to form a core element.
The solvent may be an aqueous or organic solvent or mixtures thereof. The solvent may be present in an amount effective to allow the ingredients to be extruded.
The core elements formed are then subjected to a drying step. The drying step may be conducted in a fluidised bed or drying oven.
The sustained release pharmaceutical pellet composition may be administered under a similar dosage regimen to that used in the prior art. The multi-pellet encapsulated form may for example be administered every twelve or twenty-four hours in sustained release forms.
The pharmaceutical pellet composition may be in multi-pellet encapsulated, sprinkle sachet or tableted forms.
In accordance with a further aspect of the present invention, there is provided a method of treating cardiotonic, diuretic or respiratory conditions in patients requiring such treatment which method includes administering to a patient an effective amount of a pharmaceutical sustained release pellet composition as described above.
It will be understood that the method of treating the abovementioned conditions according to this aspect of the present invention provides an advantage in reducing side effects associated with prior art sustained release products in a tablet or capsule form as described above. These side effects include headache, palpitation, dizzyness, nausea, hypotension, visual disturbance, insomnia, restlessness, confusion and diuresis.
The present invention will now be more fully described with reference to the accompanying examples. It should be understood, however, that the following description is illustrative only and should not be taken in any way as a restriction on the generality of the invention specified above.
EXAMPLE 1 
______________________________________                                    
Spheronised Core Composition 1                                            
Theophyline          25.0   kg      75.7%                                 
Sugar seeds          7.5    kg      22.7%                                 
Hydroxypropyl cellulose                                                   
                     0.52   kg      1.6%                                  
(dissolved in methanol)                                                   
Extruded Core Composition 2                                               
Theophylline         40.0   kg      87%                                   
microcrystalline cellulose                                                
                     4.0    kg      8.7%                                  
hydroxypropyl cellulose                                                   
                     2.0    kg      4.3%                                  
water                as required                                          
Hybrid Core Coating Composition A                                         
ethylcellulose N-100 104    g       59.8%                                 
polyethylene glycol 6000 NF                                               
                     50     g       28.8%                                 
hydroxypropylmethyl cellulose                                             
                     7.0    g       4.0%                                  
phthalate                                                                 
diethyl phthalate    12.9   g       7.4%                                  
methanol             1331   g                                             
methylene chloride   1331   g                                             
Hybrid Core Coating Composition B                                         
Eudragit NE30-D (as 30%                                                   
                     30.0   kg      52.45%                                
dispersion in water)                                                      
Eudragit L30D (as 30%                                                     
                     2.5    kg      4.37%                                 
dispersion in water)                                                      
polyethylene glycol 6000 NF                                               
                     6.14   kg      35.78%                                
triethyl citrate     1.27   kg      7.4%                                  
talc                 15.9   kg                                            
water                82.0   kg                                            
______________________________________
Spheronised Core Manufacture
The sugar seeds were placed in a spheroniser. The sugar seeds were then coated with a dry mixture of the active ingredients and inactive excipients whilst concimittantly adding a solution of the binder components.
The wet cores so formed were then dried in a fluidised bed dryer for 1 hour.
Extruded Core Manufacture
The components of the extruded core composition were admixed to form an extrudable composition. The composition was then extruded through a side plate extruder and the extrudate marumerised to form wet cores.
The wet cores so formed were then placed in a fluid bed dryer for 1 hour.
Pellet Manufacture
The dried spheronised cores 1 and 2 were then placed in a fluid bed coating apparatus. The hybrid core coating compositions A and B were then sprayed onto the cores 1 and 2 to form pellets A and B respectively. At the conclusion of the process, the pellets were fluid bed dried.
A dissolution test was conducted on the pellet compositions A and B utilising the test method USPXXII 1990. (Test 711). A sample is dissolved in an aqueous medium previously degassed and equilibrated to 37° C. The media are USP pH 1.2 media without enzymes and pH 7.5 phosphate buffer. A sample of known volume is withdrawn at designated time intervals from the bath as directed and subjected to a suitable assay procedure. The mg of theophylline released as a function of time is plotted as the dissolution profile.
The tests were conducted at pH 1.2 and pH 7.5.
The baskets containing the samples were rotated at approximately 50 r.p.m. and the aqueous medium maintained at approximately 37° C.
The results are given in Tables 1 to 4 and FIGS. 1 and 2 herein. The results of pellet composition B at pH 1.2 and 7.5 are given in Tables 1 and 2 respectively. The hybrid coating on pellet composition A allows dissolution at pH 1.2, a significantly faster rate of dissolution is observed at pH 7.5. The results of pellet composition A at pH 1.2 and 7.5 are given in Tables 3 and 4 respectively, similar results to that obtained from composition A.
              TABLE 1                                                     
______________________________________                                    
DISSOLUTION DATA FOR PELLET                                               
COMPOSITION B MEASURED AT pH 1.2                                          
(AVERAGED DATA FOR 6 SAMPLES)                                             
TIME  MG         (STD                                                     
MIN   RELEASED   DEV)    % RELEASED (STD DEV)                             
______________________________________                                    
 60   30.33      (1.56)   9.87      (0.41)                                
120   62.16      (2.71)  20.23      (0.68)                                
180   88.21      (3.77)  28.70      (0.92)                                
240   111.77     (4.43)  36.37      (1.09)                                
300   135.11     (5.48)  43.96      (1.26)                                
360   156.50     (3.91)  50.93      (0.67)                                
420   179.85     (6.80)  58.52      (1.54)                                
480   201.55     (5.87)  65.59      (1.12)                                
______________________________________                                    

              TABLE 2                                                     
______________________________________                                    
DISSOLUTION DATA FOR PELLET                                               
COMPOSITION B MEASURED AT pH 7.5                                          
(AVERAGED DATA FOR 6 SAMPLES)                                             
TIME  MG         (STD                                                     
MIN   RELEASED   DEV)    % RELEASED (STD DEV)                             
______________________________________                                    
 60    72.13     (1.70)  23.61      (0.38)                                
120   137.49     (3.15)  45.00      (0.67)                                
180   195.03     (3.81)  68.84      (0.87)                                
240   242.12     (4.53)  79.25      (1.03)                                
300   275.41     (2.94)  90.17      (1.67)                                
360   291.02     (1.11)  95.27      (1.20)                                
420   301.84     (3.61)  98.81      (1.04)                                
480   307.84     (2.39)  100.77     (0.81)                                
______________________________________                                    

              TABLE 3                                                     
______________________________________                                    
DISSOLUTION DATA FOR PELLET                                               
COMPOSITION A MEASURED AT pH 1.2                                          
(AVERAGED DATA FOR 3 SAMPLES)                                             
TIME  MG         (STD                                                     
MIN   RELEASED   DEV)    % RELEASED (STD DEV)                             
______________________________________                                    
 60   29.91      (0.98)   9.71      (0.31)                                
120   60.21      (2.19)  19.55      (0.69)                                
180   90.78      (1.88)  29.48      (0.58)                                
260   132.35     (2.97)  42.98      (0.93)                                
______________________________________                                    

              TABLE 4                                                     
______________________________________                                    
DISSOLUTION DATA FOR PELLET                                               
COMPOSITION A MEASURED AT pH 7.5                                          
(AVERAGED DATA FOR 3 SAMPLES)                                             
TIME  MG         (STD                                                     
MIN   RELEASED   DEV)    % RELEASED (STD DEV)                             
______________________________________                                    
 60    70.74     (0.52)  22.96      (0.20)                                
120   141.78     (0.90)  46.02      (0.36)                                
180   206.66     (1.56)  67.08      (0.53)                                
260   271.62     (3.26)  88.17      (1.19)                                
______________________________________
EXAMPLE 2 Clinical Trials
Phase I - Single Dose Study
Phase I was a three-way crossover single dose study to compare the relative bioavailability of Pellet Capsules according to the present invention with the reference product Elixophyllin® elixir, a rapid release formulation demonstrated to be completely bioavailable. The effect of food on the bioavailability of Pellet Capsules was also examined.
Both products were administered to eighteen healthy, non-smoking, adult subjects. The subjects were randomized by weight into three equal size groups I, II and III. These groups were then randomly sorted into either regimens A, B or C.
All dosing regimens were administered after a twelve hour overnight fast, and regimen B was administered immediately after food.
A - Elixophyllin® elixir (150 mg in 28 mL), administered with 152 mL water on two separate occasions six hours apart, to give a total of 300 mg of theophylline.
B - Pellet Capsules including pharmaceutical pellets according to the present invention, 300 mg of theophylline administered as a single dose with 180 mL of water immediately after the standard FDA recommended "high fat" breakfast.
C - Pellet Capsules including pharmaceutical pellets according to the present invention, 300 mg of theophylline administered as a single dose with 180 mL of water.
The washout period between each dosage regimen was one week.
Absorption
The results summarised in Table 5 indicate that the extent of absorption of Pellet Capsules taken fasting is equivalent to that of Elixophyllin®, since statistical analysis (Analysis of Variance) of the parameter area under the curve (AUCO-inf) shows no significant difference at p=0.05.
Bioavailability - Effect of food
The results summarised in Table 5 indicate that Pellet Capsules taken with food are absorbed to an equivalent extent when compared with both products taken fasting. This demonstrates that there is no reduction in the extent of absorption when Pellet Capsules are coadministered with a high fat meal and no evidence of dose dumping. When the formulation was coadministered with food, absorption was marginally delayed. This delay is of no relevance at steady state after multiple dosing.
The results summarised in Tables 5 and FIG. 3 indicate that Pellet Capsules fulfill the requirements of a sustained release product. While a single 300 mg dose of Pellet Capsules achieves a peak plasma concentration of 4.5 mg/L irrespective of the presence of food, the same dose of the reference product Elixophyllin® would achieve a peak plasma concentration approximately twice that value. In addition the time taken to reach peak plasma concentration is longer for Pellet Capsules compared with Elixophyllin®. This demonstrates that Pellet Capsules can provide therapeutic plasma theophylline concentrations within the defined narrow therapeutic concentration range with a decreased probability of theophylline toxicity due to lower peak to trough variations in blood levels.
In summary, this single dose study demonstrated the general sustained-release attributes of the Pellet Capsules theophylline formulation and highlighted the additional advantage of lack of food effect on the extent of theophylline absorption and decreased peak to trough variations in blood levels.
              TABLE 5                                                     
______________________________________                                    
Comparison of Pharmacokinetic parameters (mean ± SD) for               
single doses of theophylline obtained from 18 healthy subjects            
REGIMEN                                                                   
        A         B         C                                             
        Elix-     Pellet    Pellet  STATIS-                               
PARA-   ophyllin ®                                                    
                  Capsule as                                              
                            Capsule as                                    
                                    TICAL                                 
METER   fasting   with food fasting ANALYSIS                              
______________________________________                                    
F %     --        94.2      94.5    n.s..sup.a,c                          
                  (11.5).sup.b                                            
                            (17.0)                                        
AUC.sub.O-inf                                                             
        97.1      90.9      91.2    n.s..sup.a                            
mg.h/L  (33.7)    (31.3)    (33.8)                                        
Cpmax   9.1*.sup.d                                                        
                  4.5       4.5     A > B = C.sup.e                       
mg/L    (2.0)     (1.0)     (1.2)                                         
t.sub.max                                                                 
        1.3       9.5       8.0     B > C > A.sup.a                       
h       (0.9)     (1.7)     (1.3)                                         
t.sub.≧0.75Cpmax                                                   
        --        8.0       10.3    n.s..sup.f                            
h                 (1.3)     (3.5)                                         
t.sub.1/2                                                                 
        7.6       9.0       8.9     A < B = C.sup.a                       
h       (1.9)     (1.4)     (2.0)                                         
K -e.sub.2                                                                
        0.10      0.08      0.08    A > B = C.sup.a                       
h.sup.-I                                                                  
        (0.02)    (0.02)    (0.02)                                        
______________________________________                                    
 .sup.a Analysis of Variance                                              
 .sup.b standard deviation                                                
 .sup.c not significant at p = 0.05                                       
 .sup.d Cpmax  for comparison the Elixophyllin is expressed as twice the  
 value obtained following the first dose.                                 
 .sup.e Newman-Keuls Multiple Range Test for significance                 
 .sup.f Student's Paired ttest
Phase II - Multiple Dose Study
Phase II was a three-way crossover multiple dose study to compare the plasma steady state theophylline concentrations produced by three different formulations; Pellet Capsule pelletised sustained release capsules, Theo-Dur® sustained release tablets and Neulin® tablets. Neulin® is an immediate release theophylline product.
All products were administered to eighteen healthy, nonsmoking, adult subjects. The subjects were randomised using Elixophyllin® clearance values and then randomly sorted into either regimens A, B or C. Each subject's dose was tailored using single dose study data to obtain steady state plasma theophylline concentrations of approximately 10 mg/L.
All dosing regimens were administered with 180 mL of water. The products were administered at equal dosing intervals for six days. The subjects consumed a Xanthine-free but otherwise unrestricted diet. Sampling commenced after five days of chronic dosing.
A - Neulin® tablets administered four times a day (six hourly)
B - Pellet Capsule capsules administered twice a day (twelve hourly)
C - Theo-Dur® tablets administered twice a day (twelve hourly).
Absorption
The results summarised in Table 6 indicate that the extent of theophylline absorption is comparable between the products Pellet Capsules, Theo-Dur® and Neulin® after multiple dosing. In addition, the bioavailability (F) of theophylline is comparable between the sustained release products Pellet Capsules and Theo-Dur® relative to Neulin®.
Twice Daily Dosing
The results summarised in FIG. 4 indicate that after steady state plasma theophylline concentrations were achieved, 75% of the peak plasma theophylline concentrations were maintained throughout the dosing interval. These prolonged values demonstrate a sustained period of therapeutic plasma theophylline concentration, indicating that no more than twice daily dosing is necessary with Pellet Capsules to achieve maintenance of plasma concentrations within the recommended therapeutic range.
Fluctuations
The efficacy and toxicity of theophylline is directly related to the plasma theophylline concentration. The optimum therapeutic concentration range is 5 to 20 mg/L (Hendeles and Weinberger, 1983). Thus theophylline has a narrow therapeutic index. Plasma concentrations below 5 mg/L generally result in less than optimal bronchodilatation while concentrations above 20 mg/L are often associated with theophylline toxicity.
Theophylline is used prophylactically in the management of asthma and chronic obstructive airways disease (COAD), requiring continuous theophylline therapy for prolonged periods of time. When Pellet Capsules are administered at the appropriate dosing rate, the plasma theophylline concentrations observed are maintained within the defined therapeutic range.
The results summarised in Tables 6, 7 and 8 indicate that over a twenty four hour period, Pellet Capsules exhibit significantly less fluctuation (percentage fluctuation) in steady state plasma theophylline concentration compared to Theo-Dur®. This demonstrates that Pellet Capsules achieve more reliable plasma theophylline concentrations within the therapeutic range and is a more reliable sustained-release theophylline product.
Diurnal Variation
Analysis of the percentage fluctuation at steady state plasma theophylline concentrations (Student's paired t-test) (Tables 6, 7 and 8) reveals that there is less diurnal variation in plasma theophylline concentrations when Pellet Capsules are compared with Theo-Dur®. There is no difference in the extent of fluctuation during a twelve hour dosage interval either during the day or during the night with Pellet Capsules. In contrast, Theo-Dur® exhibits significantly more fluctuation in plasma theophylline concentration during the day than during the night. Pellet Capsules exhibit less fluctuation in plasma theophylline concentration during the day compared to Theo-Dur® although the extent of fluctuation during the night is comparable between the two sustained release products. These results confirm the diurnal variation reported in the literature for other commercially available products (Reed et al., 1986) and emphasise that Pellet Capsules is an improved formulation.
The multiple dose study confirms the results of the single dose study and highlights the additional advantages of significantly less diurnal variation as percent fluctuations in plasma theophylline concentrations at steady state.
                                  TABLE 6                                 
__________________________________________________________________________
Steady state pharmacokinetic parameters (mean ± SD) for                
theophylline following administration of 3 theophylline                   
preparations to 18 healthy subjects                                       
           REGIMEN                                                        
           A      B           C       STATISTICAL                         
PARAMETER  NEULIN ®                                                   
                  PELLET CAPSULES                                         
                              THEO-DUR ®                              
                                      ANALYSIS                            
__________________________________________________________________________
F%         --     102.3       103     n.s..sup.a,c                        
                  (14.4).sup.b                                            
                              (11.2)                                      
AUC        208.7  211.8       214.3   n.s..sup.d                          
TOTAL 24 hr                                                               
mg.h/L     (31.7) (33.3)      (37.1)                                      
% FLUCTUATION                                                             
           54.0   26.3        44.8    A > C > B.sup.d                     
day.sup.e  (16.0) (10.5)      (15.3)  B C.sup.a                           
% FLUCTUATION                                                             
           58.5   25.8        33.9    A > C = B.sup.d                     
night      (19.5) (9.1)       (10.5)  n.s..sup.a                          
% FLUCTUATION                                                             
           66.5   36.7        53.1    A > C > B.sup.d                     
total      (18.9) (13.7)      (14.1)  B C.sup.a                           
Cp.sub.min day                                                            
           6.9    7.8         7.2     B > C = A.sup.d                     
mg/L       (1.3)  (1.5)       (1.3)                                       
Cp.sub.min night                                                          
           7.0    7.7         7.8     A < B = C.sup.d                     
mg/L       (1.3)  (1.4)       (1.3)                                       
Cp.sub.max day                                                            
           10.5   9.8         10.4    n.s..sup.d                          
mg/L       (1.8)  (1.6)       (1.9)                                       
Cp.sub.max night                                                          
           10.9   9.6         10.4    B < C = A.sup.d                     
mg/L       (1.4)  (1.3)       (2.1)                                       
t.sub.≧0.75CPmax                                                   
           --     11.7        9.7     B > C.sup.a                         
h (day)           (.06)       (2.1)                                       
t.sub.≧0.75CPmax                                                   
           --     11.8        10.9    B > C.sup.a                         
h (night)  (0.4)  (1.4)                                                   
__________________________________________________________________________
 .sup.a Student's paired ttest                                            
 .sup.b standard deviation                                                
 .sup.c not significant at p = 0.05                                       
 .sup.d Analysis of Variance                                              
 .sup.e % Fluctuation =-                                                  
 ##STR1##                                                                 

                                  TABLE 7                                 
__________________________________________________________________________
Comparison of the mean (±SD) values for the day and night              
time intervals at steady state plasma theophylline                        
concentrations obtained from 18 healthy subjects.                         
                DAY     NIGHT   STATISTICAL                               
PARAMETER                                                                 
         PRODUCT                                                          
                8 a.m.-8 p.m.                                             
                        8 p.m.-8 a.m.                                     
                                ANALYSIS.sup.a                            
__________________________________________________________________________
AUC      Pellet Caps                                                      
                106.7                                                     
                    (18.8).sup.b                                          
                        105.1                                             
                            (15.6)                                        
                                n.s..sup.c                                
mg.h/L   Theo-Dur ®                                                   
                106.0                                                     
                    (18.1)                                                
                        108.4                                             
                            (20.4)                                        
                                n.s.                                      
% FLUCT. Pellet Caps                                                      
                26.3                                                      
                    (10.5)                                                
                        25.8                                              
                            (9.1)                                         
                                n.s.                                      
steady-  Theo-Dur ®                                                   
                44.8                                                      
                    (15.3)                                                
                        33.9                                              
                            (10.5)                                        
                                day > night                               
state                                                                     
Cp.sub.max                                                                
         Pellet Caps                                                      
                9.8 (1.6)                                                 
                        9.6 (1.3)                                         
                                n.s.                                      
mg/L     Theo-Dur ®                                                   
                10.4                                                      
                    (1.9)                                                 
                        10.4                                              
                            (2.1)                                         
                                n.s.                                      
Cp.sub.min                                                                
         Pellet Caps                                                      
                7.8 (1.5)                                                 
                        7.7 (1.4)                                         
                                n.s.                                      
mg/L     Theo-Dur ®                                                   
                7.2 (1.3)                                                 
                        7.7 (1.3)                                         
                                night > day                               
t ≧ 0.75                                                           
         Pellet Caps                                                      
                11.7                                                      
                    (0.6)                                                 
                        11.8                                              
                            (0.4)                                         
                                n.s.                                      
Cp.sub.max h                                                              
         Theo-Dur ®                                                   
                9.7 (2.1)                                                 
                        10.9                                              
                            (1.4)                                         
                                n.s.                                      
__________________________________________________________________________
 .sup.a student's paired ttest                                            
 .sup.b standard deviation                                                
 .sup.c not significant at p = 0.05                                       

              TABLE 8                                                     
______________________________________                                    
Comparisons of the number of subjects and fluctuations of                 
plasma theophylline concentrations for the sustained-release              
products at steady-state.                                                 
                 Number of subjects                                       
                       Pellet   Theo-Dur ®                            
Time (h)                                                                  
        Fluctuation (%)                                                   
                       capsules tablets                                   
______________________________________                                    
0-24    <30            6        1                                         
(night/day)                                                               
        30-40          8        l                                         
        40-50          1        7                                         
        >50            3        9                                         
0-12    <30            11       7                                         
(night) 30-40          6        4                                         
        40-50          1        7                                         
        >50            0        0                                         
12-24   <30            13       2                                         
(day)   30-40          3        4                                         
        40-50          2        7                                         
        >50            0        5                                         
______________________________________
Finally, it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the present invention as outlined herein.

Claims (14)

I claim:
1. A pH-dependent sustained release pharmaceutical pellet composition for administration to a patient at a predetermined dosage and interval which comprises: a core element containing a therapeutically effective amount of methylated xanthine or a salt thereof as the active ingredient and a coating on said core element which comprises the following components:
(a) at least 40% of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and contributes to the control of the rate of release of the active ingredient in the stomach and intestines;
(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;
(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach; said percentages being by weight based on total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval, said coated core element having a diameter of from 510 to 2400 microns.
2. A sustained release pharmaceutical pellet composition according to claim 1, wherein the methylated xanthine salt is an ethylene diamine salt of theophylline.
3. The sustained release pharmaceutical pellet composition of claim 1 wherein the rate of release in the intestine is 1.2 to 3 times greater than the rate of release in the stomach.
4. The sustained release pharmaceutical pellet composition of claim 1 wherein the active ingredient has a first dissolution profile measured at a pH of from 1 to 4, and a second dissolution profile measured at a pH of about 7.5 and wherein said first and second dissolution profile are each at least equal to the minimum dissolution required to provide substantially the same bio-availability as with an immediate release oral dosage form.
5. The sustained release pharmaceutical pellet composition of claim 1 wherein the core coating contains:
as component (a), ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof;
as component (b), cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid:acrylic acid ester copolymer, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate and mixtures thereof; and
as component (c), polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol having a molecular weight of from 1700 to 20,000, polyvinyl alcohol and monomers therefor and mixtures thereof.
6. A sustained release pharmaceutical pellet composition according to claim 5 wherein the core element has a formulation
______________________________________                                    
Theophylline        20 to 90% by weight                                   
Hydroxypropylcellulose                                                    
                    0.1 to 10% by weight                                  
Microcrystalline cellulose                                                
                    1 to 20% by weight                                    
Lactose             0 to 60% by weight.                                   
______________________________________
7. The sustained release pharmaceutical pellet composition of claim 5 wherein the core coating comprises:
40 to 70% by weight of component (a);
2.5-10% by weight of component (b); and
20-40% by weight of component (c).
8. The sustained release pharmaceutical pellet composition of claim 5 wherein the core coating also includes up to 75% of a filler selected from silicon dioxide, titanium dioxide, talc, alumina, starch, kaolin, polacrilin potassium, powdered cellulose and microcrystalline cellulose and mixtures thereof and from 2.5 to 50% of plasticizer selected from diethyl phthalate, triethyl citrate, triethyl acetyl citrate, triethyl acetin, tributyl citrate, polyethylene glycol or glycerol, said percentages being based on the total weight of the core coating.
9. The sustained release pharmaceutical pellet composition of claim 5 wherein the rate of release in the intestine is 1.2 to 3 times greater than the rate of release in the stomach.
10. A sustained release pharmaceutical pellet composition according to claim 8 wherein the core coating contains:
______________________________________                                    
Ethyl cellulose   40 to 70%                                               
Hydroxypropylmethyl                                                       
                  2.5 to 10%                                              
cellulose phthalate                                                       
Polyethylene glycol                                                       
                  20 to 40%                                               
Diethyl phthalate 2.5 to 30%                                              
______________________________________
11. A sustained release pharmaceutical pellet composition according to claim 8 wherein the core coating contains:
______________________________________                                    
Eudragit NE30D      40-70%                                                
Eudragit L30D       2.5-10%                                               
polyethylene glycol 6000 NF                                               
                    20-40%                                                
Triethylcitrate     2.5-30%                                               
______________________________________
12. A method for treating cardiotonic, diuretic or respiratory conditions in a patient which comprises administering to said patient at a predetermined dosage and interval a pH-dependent sustained release pharmaceutical pellet composition which comprises: a core element containing a therapeutically effective amount of methylated xanthine or a salt thereof as the active ingredient and a coating on said core element which comprises the following components:
(a) at least 40% of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and contributes to the control of the rate of release of the active ingredient in the stomach and intestines;
(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;
(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach; said percentages being by weight based on total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval, said coated core element having a diameter of from 510 to 2400 microns.
13. A pH-dependent sustained release pharmaceutical pellet composition for administration to a patient at a predetermined dosage and interval which comprises: a core element containing a therapeutically effective amount of methylated xanthine or a salt thereof as the active ingredient and a coating on said core element which comprises the following components:
(a) at least 40% of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and is composed of ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof which contributes to the control of the release of the active ingredient in the stomach and intestines;
(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;
(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach;
said percentages being by weight based on total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval, said coated core element having a diameter of from 510 to 2400 microns.
14. A method for treating cardiotonic, diuretic or respiratory conditions in a patient which comprises administering to said patient at a predetermined dosage and interval a pH-dependent sustained release pharmaceutical pellet composition which comprises: a core element containing a therapeutically effective amount of methylated xanthine or a salt thereof as the active ingredient and a coating on said core element which comprises the following components:
(a) at least 40% of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and is composed of ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof which contributes to the control of the release of the active ingredient in the stomach and intestines;
(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;
(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach;
said percentages being by weight based on total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval, said coated core element having a diameter of from 510 to 2400 microns.
US07/767,342 1989-01-06 1991-09-27 Theophylline dosage form Expired - Fee Related US5196203A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/767,342 US5196203A (en) 1989-01-06 1991-09-27 Theophylline dosage form

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPJ2191 1989-01-06
AUPJ219189 1989-01-06
US45719889A 1989-12-29 1989-12-29
US07/767,342 US5196203A (en) 1989-01-06 1991-09-27 Theophylline dosage form

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US45719889A Continuation 1989-01-06 1989-12-29

Publications (1)

Publication Number Publication Date
US5196203A true US5196203A (en) 1993-03-23

Family

ID=27157473

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/767,342 Expired - Fee Related US5196203A (en) 1989-01-06 1991-09-27 Theophylline dosage form

Country Status (1)

Country Link
US (1) US5196203A (en)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378474A (en) * 1989-01-06 1995-01-03 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5958452A (en) * 1994-11-04 1999-09-28 Euro-Celtique, S.A. Extruded orally administrable opioid formulations
US6068855A (en) * 1994-11-03 2000-05-30 Euro-Celtique S. A. Pharmaceutical composition containing a fusible carrier and method for producing the same
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US6254887B1 (en) 1993-05-10 2001-07-03 Euro-Celtique S.A. Controlled release tramadol
US6399096B1 (en) 1995-09-22 2002-06-04 Euro-Celtique S.A. Pharmaceutical formulation
US20030170304A1 (en) * 1998-11-02 2003-09-11 Devane John G. Multiparticulate modified release composition
US20040047907A1 (en) * 2000-10-30 2004-03-11 Benjamin Oshlack Controlled release hydrocodone formulations
US20040096500A1 (en) * 1991-11-27 2004-05-20 Benjamin Oshlack Controlled release oxycodone compositions
US20040170680A1 (en) * 2001-05-02 2004-09-02 Benjamin Oshlack Once-a-day oxycodone formulations
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US20040266807A1 (en) * 1999-10-29 2004-12-30 Euro-Celtique, S.A. Controlled release hydrocodone formulations
US20060099263A1 (en) * 1993-05-27 2006-05-11 Edgren David E Antidepressant dosage form
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
US20060163515A1 (en) * 2003-06-17 2006-07-27 Ruschke Ricky R Fluid handling device and method of making same
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20060269604A1 (en) * 1993-11-23 2006-11-30 Purdue Pharma L.P. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
US20080055036A1 (en) * 2006-08-29 2008-03-06 International Business Machines Corporation Electrical component tuned by conductive layer deletion
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
US20080069870A1 (en) * 2005-04-12 2008-03-20 Elan Corporation Pic Controlled Release Compositions Comprising a Cephalosporin for the Treatment of a Bacterial Infection
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
WO2009112874A1 (en) * 2008-03-10 2009-09-17 Eurodrug Laboratories B.V. Modified release composition comprising doxofylline
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US20100260839A1 (en) * 2007-11-16 2010-10-14 Asahi Kasei Chemicals Corporation Aqueous film coating solution, film coated granule and tablet using the same
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US8557286B1 (en) 1999-04-22 2013-10-15 Euroceltique, S.A. Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2753310B1 (en) 2011-09-07 2021-03-24 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4083949A (en) * 1973-07-17 1978-04-11 Byk Gulden Lomberg Chemische Fabrik Gmbh New oral form of medicament and a method for producing it
GB1568837A (en) * 1975-10-10 1980-06-04 Squibb & Sons Inc Controlled release tablet
US4367217A (en) * 1980-01-12 1983-01-04 Boehringer Ingelheim Gmbh Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
GB2101069A (en) * 1981-05-29 1983-01-12 Tanabe Seiyaku Co Ethylcellulose microcapsules
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
AU4323685A (en) * 1984-06-04 1985-12-12 Sterling Drug Inc. Sustained release medicament in polymer coated enteric composition
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
AU5146085A (en) * 1984-12-20 1986-07-17 Rhone-Poulenc Sante Compositions for coating feedingstuff additives intended for ruminants and feedingstuff additives thus coated
US4661162A (en) * 1983-04-18 1987-04-28 Sankyo Company, Limited Enteric-soluble preparations
US4708874A (en) * 1985-03-13 1987-11-24 Rijksuniversiteit Groningen Devices for the controlled release of active substances, as well as process for the preparation thereof
US4713248A (en) * 1984-02-10 1987-12-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
EP0260236A1 (en) * 1986-08-26 1988-03-16 ASTA Pharma Aktiengesellschaft Composition comprising L-dopa
AU8199787A (en) * 1986-12-02 1988-06-02 Euro-Celtique S.A. Spheroids
EP0287536A1 (en) * 1987-03-16 1988-10-19 Lejus Medical Aktiebolag Pharmaceutical quinidine composition
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US4803080A (en) * 1984-12-21 1989-02-07 Byk Gulden Lomberg Chemische Fabrik Sustained-release theophylline formulation
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
EP0327295A2 (en) * 1988-02-01 1989-08-09 F.H. FAULDING &amp; CO. LTD. Tetracycline dosage form

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4083949A (en) * 1973-07-17 1978-04-11 Byk Gulden Lomberg Chemische Fabrik Gmbh New oral form of medicament and a method for producing it
GB1568837A (en) * 1975-10-10 1980-06-04 Squibb & Sons Inc Controlled release tablet
US4367217A (en) * 1980-01-12 1983-01-04 Boehringer Ingelheim Gmbh Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
GB2101069A (en) * 1981-05-29 1983-01-12 Tanabe Seiyaku Co Ethylcellulose microcapsules
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4661162A (en) * 1983-04-18 1987-04-28 Sankyo Company, Limited Enteric-soluble preparations
US4713248A (en) * 1984-02-10 1987-12-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
EP0164959A2 (en) * 1984-06-04 1985-12-18 Sterwin Ag. Pharmaceutical composition in sustained release unit dose form and process for its preparation
AU4323685A (en) * 1984-06-04 1985-12-12 Sterling Drug Inc. Sustained release medicament in polymer coated enteric composition
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
AU5146085A (en) * 1984-12-20 1986-07-17 Rhone-Poulenc Sante Compositions for coating feedingstuff additives intended for ruminants and feedingstuff additives thus coated
US4803080A (en) * 1984-12-21 1989-02-07 Byk Gulden Lomberg Chemische Fabrik Sustained-release theophylline formulation
US4708874A (en) * 1985-03-13 1987-11-24 Rijksuniversiteit Groningen Devices for the controlled release of active substances, as well as process for the preparation thereof
EP0260236A1 (en) * 1986-08-26 1988-03-16 ASTA Pharma Aktiengesellschaft Composition comprising L-dopa
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
EP0270305A2 (en) * 1986-12-02 1988-06-08 Euroceltique S.A. Spheroids
AU8199787A (en) * 1986-12-02 1988-06-02 Euro-Celtique S.A. Spheroids
US4844910A (en) * 1986-12-02 1989-07-04 Euroceltique, S.A. Spheroids
EP0287536A1 (en) * 1987-03-16 1988-10-19 Lejus Medical Aktiebolag Pharmaceutical quinidine composition
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
EP0327295A2 (en) * 1988-02-01 1989-08-09 F.H. FAULDING &amp; CO. LTD. Tetracycline dosage form

Cited By (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378474A (en) * 1989-01-06 1995-01-03 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US20040096500A1 (en) * 1991-11-27 2004-05-20 Benjamin Oshlack Controlled release oxycodone compositions
US20040185098A1 (en) * 1991-11-27 2004-09-23 Benjamin Oshlack Controlled release oxycodone compositions
US20060057210A1 (en) * 1991-11-27 2006-03-16 Purdue Pharma L.P. Controlled release oxycodone compositions
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20100092570A1 (en) * 1992-11-25 2010-04-15 Purdue Pharma L.P. Controlled release oxycodone compositions
US7074430B2 (en) 1993-05-10 2006-07-11 Euro-Celtique S.A. Controlled release tramadol tramadol formulation
US20090117191A1 (en) * 1993-05-10 2009-05-07 Purdue Pharma Products L.P. Controlled release tramadol formulations
US20060269603A1 (en) * 1993-05-10 2006-11-30 Euro-Celtique S.A. Controlled release tramadol formulations
US6326027B1 (en) 1993-05-10 2001-12-04 Euro-Celtique S.A. Controlled release formulation
US6254887B1 (en) 1993-05-10 2001-07-03 Euro-Celtique S.A. Controlled release tramadol
US20060099263A1 (en) * 1993-05-27 2006-05-11 Edgren David E Antidepressant dosage form
US20100034876A1 (en) * 1993-06-18 2010-02-11 Purdue Pharma L.P. Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US6143322A (en) * 1993-07-01 2000-11-07 Purdue Pharma L.P. Method of treating humans with opioid formulations having extended controlled release
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US6143328A (en) * 1993-07-27 2000-11-07 Euro-Celtique, S.A. Sustained release compositions and a method of preparing pharmaceutical compositions
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US20060269604A1 (en) * 1993-11-23 2006-11-30 Purdue Pharma L.P. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20070237832A1 (en) * 1993-11-23 2007-10-11 Purdue Pharma L.P. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US20080031963A1 (en) * 1993-11-23 2008-02-07 Purdue Pharma L.P. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5965163A (en) * 1993-11-23 1999-10-12 Euro-Celtique, S.A. Substained release compositions and a method of preparing pharmaceutical compositions
US20070237833A1 (en) * 1993-11-23 2007-10-11 Purdue Pharma L.P. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US6162467A (en) * 1993-11-23 2000-12-19 Euro-Celtique, S.A. Sustained release compositions and a method of preparing pharmaceutical compositions
US20100209351A1 (en) * 1993-11-23 2010-08-19 Sackler Richard S Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US6068855A (en) * 1994-11-03 2000-05-30 Euro-Celtique S. A. Pharmaceutical composition containing a fusible carrier and method for producing the same
US5958452A (en) * 1994-11-04 1999-09-28 Euro-Celtique, S.A. Extruded orally administrable opioid formulations
US6706281B2 (en) 1994-11-04 2004-03-16 Euro-Celtique, S.A. Melt-extrusion multiparticulates
US6261599B1 (en) 1994-11-04 2001-07-17 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6743442B2 (en) 1994-11-04 2004-06-01 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6335033B2 (en) 1994-11-04 2002-01-01 Euro-Celtique, S.A. Melt-extrusion multiparticulates
US7510727B2 (en) 1994-11-04 2009-03-31 Purdue Pharma L.P. Melt-extrusion multiparticulates
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6399096B1 (en) 1995-09-22 2002-06-04 Euro-Celtique S.A. Pharmaceutical formulation
US8506998B2 (en) 1995-09-22 2013-08-13 Euro-Celtique S.A. Pharmaceutical formulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US6793936B2 (en) 1998-11-02 2004-09-21 Elan Corporation, Plc Multiparticulate modified release composition
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US6902742B2 (en) 1998-11-02 2005-06-07 Elan Corporation, Plc Multiparticulate modified release composition
US20040197405A1 (en) * 1998-11-02 2004-10-07 Elan Corporation, Plc Multiparticulate modified release composition
US20030170304A1 (en) * 1998-11-02 2003-09-11 Devane John G. Multiparticulate modified release composition
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US8119163B2 (en) 1998-11-02 2012-02-21 Alkermes Pharma Ireland Limited Nanoparticulate and controlled release compositions comprising cefditoren
US20080279929A1 (en) * 1998-11-02 2008-11-13 Elan Corproation Plc Nanoparticulate and Controlled Release Compositions Comprising Cefditoren
US8557286B1 (en) 1999-04-22 2013-10-15 Euroceltique, S.A. Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
US8980291B2 (en) 1999-10-29 2015-03-17 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7943174B2 (en) 1999-10-29 2011-05-17 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10076516B2 (en) 1999-10-29 2018-09-18 Purdue Pharma L.P. Methods of manufacturing oral dosage forms
US9675611B1 (en) 1999-10-29 2017-06-13 Purdue Pharma L.P. Methods of providing analgesia
US9669022B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9669024B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9320717B2 (en) 1999-10-29 2016-04-26 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9278074B2 (en) 1999-10-29 2016-03-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9056107B1 (en) 1999-10-29 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8975273B2 (en) 1999-10-29 2015-03-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20040266807A1 (en) * 1999-10-29 2004-12-30 Euro-Celtique, S.A. Controlled release hydrocodone formulations
US9517236B2 (en) 2000-10-30 2016-12-13 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572805B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10022368B2 (en) 2000-10-30 2018-07-17 Purdue Pharma L.P. Methods of manufacturing oral formulations
US9682077B2 (en) 2000-10-30 2017-06-20 Purdue Pharma L.P. Methods of providing analgesia
US9669023B2 (en) 2000-10-30 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20110038927A1 (en) * 2000-10-30 2011-02-17 Purdue Pharma Lp Controlled release hydrocodone formulations
US9572804B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9526724B2 (en) 2000-10-30 2016-12-27 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7514100B2 (en) 2000-10-30 2009-04-07 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9504681B2 (en) 2000-10-30 2016-11-29 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8142811B2 (en) 2000-10-30 2012-03-27 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8231898B2 (en) 2000-10-30 2012-07-31 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9289391B2 (en) 2000-10-30 2016-03-22 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8361499B2 (en) 2000-10-30 2013-01-29 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9205056B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8551520B2 (en) 2000-10-30 2013-10-08 Purdue Pharma L.P. Controlled release hydrocodone
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US8647667B2 (en) 2000-10-30 2014-02-11 Purdue Pharma, L.P. Controlled release hydrocodone formulations
US8715721B2 (en) 2000-10-30 2014-05-06 Purdue Pharma L.P. Controlled release hydrocodone
US9205055B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8951555B1 (en) 2000-10-30 2015-02-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9198863B2 (en) 2000-10-30 2015-12-01 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20040047907A1 (en) * 2000-10-30 2004-03-11 Benjamin Oshlack Controlled release hydrocodone formulations
US9023401B1 (en) 2000-10-30 2015-05-05 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9060940B2 (en) 2000-10-30 2015-06-23 Purdue Pharma L.P. Controlled release hydrocodone
US9056052B1 (en) 2000-10-30 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9750736B2 (en) 2001-05-02 2017-09-05 Purdue Pharma L.P. Oxycodone formulations
US7846476B2 (en) 2001-05-02 2010-12-07 Purdue Pharma L.P. Once-a-day oxycodone formulations
US10660886B2 (en) 2001-05-02 2020-05-26 Purdue Pharma L.P. Oxycodone formulations
US20040170680A1 (en) * 2001-05-02 2004-09-02 Benjamin Oshlack Once-a-day oxycodone formulations
US9655894B2 (en) 2001-05-02 2017-05-23 Purdue Pharma L.P. Once-A day oxycodone formulations
US9655893B2 (en) 2001-05-02 2017-05-23 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US8038123B2 (en) 2003-06-17 2011-10-18 Filtertek Inc. Fluid handling device and method of making same
US20060163515A1 (en) * 2003-06-17 2006-07-27 Ruschke Ricky R Fluid handling device and method of making same
US7520489B2 (en) 2003-06-17 2009-04-21 Filtertek Inc. Fluid handling device and method of making same
US20090184275A1 (en) * 2003-06-17 2009-07-23 Filtertek Inc. Fluid handling device and method of making same
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
US20080069870A1 (en) * 2005-04-12 2008-03-20 Elan Corporation Pic Controlled Release Compositions Comprising a Cephalosporin for the Treatment of a Bacterial Infection
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
US20080055036A1 (en) * 2006-08-29 2008-03-06 International Business Machines Corporation Electrical component tuned by conductive layer deletion
US20100260839A1 (en) * 2007-11-16 2010-10-14 Asahi Kasei Chemicals Corporation Aqueous film coating solution, film coated granule and tablet using the same
US8268356B2 (en) 2007-11-16 2012-09-18 Asahi Kasei Chemicals Corporation Aqueous film coating solution, film coated granule and tablet using the same
WO2009112874A1 (en) * 2008-03-10 2009-09-17 Eurodrug Laboratories B.V. Modified release composition comprising doxofylline
WO2009112436A1 (en) * 2008-03-10 2009-09-17 Eurodrug Laboratories B.V. Modified release composition comprising doxofylline
AU2009224801B2 (en) * 2008-03-10 2014-06-05 Pacific Healthcare (Thailand) Co. Ltd Modified release composition comprising doxofylline
EP2753310B1 (en) 2011-09-07 2021-03-24 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal

Similar Documents

Publication Publication Date Title
US5196203A (en) Theophylline dosage form
EP0377517A2 (en) Theophylline dosage form
EP0653935B1 (en) Pelletised pharmaceutical composition
EP0609961B1 (en) Sustained release pharmaceutical composition
US5296236A (en) Controlled release therapeutic system for a liquid pharmaceutical formulations
CA2124012C (en) Sustained release diltiazem formulation
US5576022A (en) Controlled release tacrine drug delivery systems and methods for preparing same
US6077533A (en) Powder-layered oral dosage forms
US4957745A (en) Pharmaceutical preparation
EP0711152B1 (en) Powder-layered oral dosage forms
US5670172A (en) Pharmaceutical spheroid formulation
US5002776A (en) Controlled absorption diltiazem formulations
EP1094790B1 (en) Sustained release pharmaceutical preparation comprising phenytoin sodium
US6699506B1 (en) Pharmaceutical composition with extended release of Milnacipran
US5277916A (en) Tetracycline dosage form
CZ5097A3 (en) Pharmaceutical dosing form with controlled release, suitable for moguistein administration, process of its preparation and pharmaceutical composition
SE509029C2 (en) Long-acting diclofenac sodium preparations
US7135465B2 (en) Sustained release beadlets containing stavudine
KR970001656B1 (en) Controlled absorption diltiazem formulations
RU2275191C2 (en) Pharmaceutical compositions consisting of multiple particles with sustained-release of serotonin reuptake selective inhibitor
US20080193537A1 (en) Morphine Sulfate Formulations
AU670958B2 (en) Pelletised pharmaceutical composition
AU614328B2 (en) Tetracycline dosage form

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 20010323

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362